We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
This clone identifies IgG4 positive plasma cells, which are increased in IgG4-related sclerosing disease. The immunohistochemical evaluation for IgG4-related disease (IRD) is commonly based on the percentage of IgG4-specific plasma cells among the total IgG-positive plasma cells (usually over 40%, or over 50 IgG4+ plasma cells per 400x field, in this disease, see reference). Therefore, PhenoPath's assay employs antibodies to both IgG4 and total IgG. In some cases, antibodies to CD38 or IgA may also be employed, particularly when total IgG+ plasma cells appear to represent a minority of the total plasma cells, as is common in the gastrointestinal tract. Our pathologists are happy to answer questions concerning interpretation of IgG4 or PhenoPath's testing policy. Ref: Mod Pathol 25:1181-92, 2012 Subcellular Localization: Cytoplasmic
Organ: Colon & Other GI
Disease State: Benign/reactive sclerosing lesion
CPT Code(s): 88360 and 88342 and/or 88341 x number of additional antibodies performed (reference only; CPTs may vary)
Turnaround Time: Within 1-2 business days of receipt
Schedule: Monday - Friday
• Formalin-fixed, paraffin-embedded (FFPE) tissue block or cell block - OR - • Minimum of 5 unstained slides cut at 4µm